Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
NOVARESE, 89% Increase in Net Income for the Last Fiscal Year, Current period performance is undisclosed.
9160 NOVARESE,Inc. 【IFRS】
Earnings ReportNOVARESE,Inc. <9160> [TSE Std] announced its financial results (based on IFRS) after the market closed on February 13th (15:30). The consolidated net income for the fiscal year ended December 2025 expanded to 89.4% from the previous period to 1.25 billion yen, exceeding the previous forecast of 1.00 billion yen. This marks the fifth consecutive term of revenue growth. Furthermore, the company did not disclose the performance outlook for the fiscal year ending December 2026.
In the most recent three-month period, from October to December (4Q), the consolidated net income grew 28.2% from the same period last year, reaching 1.17 billion yen. The operating profit margin rose from 21.2% in the same period last year to 23.4%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2023 | 18,265 | 1,539 | 1,230 | 942 | 37.7 | 0 | Feb 14, 2024 | IFRS |
| Dec, 2024 | 19,299 | 1,337 | 975 | 663 | 26.6 | 0 | Feb 14, 2025 | IFRS |
| Dec, 2025 | 22,039 | 2,247 | 1,849 | 1,256 | 50.2 | 0 | Feb 13, 2026 | IFRS |
| YoY | +14.2% | +68.1% | +89.6% | +89.4% | +88.9% |
Full Year Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2025 Guidance | 20,505 | 1,878 | 1,504 | 1,008 | 40.2 | 0 | Feb 14, 2025 | IFRS |
| Dec, 2025 Results | 22,039 | 2,247 | 1,849 | 1,256 | 50.2 | 0 | Feb 13, 2026 | IFRS |
| Revision Rate | +7.5% | +19.6% | +22.9% | +24.6% | +24.8% |
Current Period Guidance
H1 Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jan - Jun, 2025 | 9,703 | 490 | 279 | 216 | 8.7 | 0 | Aug 14, 2025 | IFRS |
| Jan - Jun, 2026 Guidance | ー | ー | ー | ー | - | 0 | Feb 13, 2026 | IFRS |
| YoY | - | - | - | - | - |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2024 | 19,299 | 1,337 | 975 | 663 | 26.6 | 0 | Feb 14, 2025 | IFRS |
| Dec, 2025 | 22,039 | 2,247 | 1,849 | 1,256 | 50.2 | 0 | Feb 13, 2026 | IFRS |
| Dec, 2026 Guidance | ー | ー | ー | ー | - | 0 | Feb 13, 2026 | IFRS |
| YoY | - | - | - | - | - |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 6,749 | 1,433 | 1,359 | 918 | 36.8 | 21.2 | Feb 14, 2025 | IFRS |
| Jan - Mar, 2025 | 4,159 | -155 | -243 | -121 | -4.8 | -3.7 | May 15, 2025 | IFRS |
| Apr - Jun, 2025 | 5,544 | 645 | 522 | 337 | 13.5 | 11.6 | Aug 14, 2025 | IFRS |
| Jul - Sep, 2025 | 4,478 | -82 | -191 | -137 | -5.5 | -1.8 | Nov 14, 2025 | IFRS |
| Oct - Dec, 2025 | 7,858 | 1,839 | 1,761 | 1,177 | 47.0 | 23.4 | Feb 13, 2026 | IFRS |
| YoY | +16.4% | +28.3% | +29.6% | +28.2% | +27.8% |
Related Articles
Cuorips, Ordinary Profit Forecast for the Fiscal Year Loss Widened in Downward Revision
Nxera Pharma, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.
MEEQ, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 63%, Oct-Dec Ordinary Profit Increases by 2.1 times
Thinca, The Current Fiscal Year's Net Income Turns to Loss
OPTORUN, 2.3 times Increase in Ordinary Profit for The Current Fiscal Year, Dividend Raised by 2 Yen
EYEZ INC, Ordinary Profit/Loss Unexpectedly Turn to Loss for Last Fiscal Year, Returning to Profitability This Year
WILSON LEARNING WORLDWIDE, Apr-Dec (Cumulative 3Q) Ordinary Profit Loss Narrows, Oct-Dec Ordinary Profit Loss Narrows
Excite Holdings, Apr-Dec (Cumulative 3Q) Net Income Decreases by 92%
Appier Group, 35% Increase in Net Income, Record High for The First Time in Two Years, Dividend Raised by 0.05 Yen
SOLIZE , Last Fiscal Year's Ordinary Profit Exceeds Expectations, 6.1 times Increase in The Current Fiscal Year